Cumulus Neuroscience to Present Data at the International Society for CNS Clinical Trials and Methodology (ISCTM) Autumn Conference and the 38th European College of Neuropsychopharmacology (ECNP) Annual Meeting

  • Poster presentations to take place at ISCTM on Friday October 10th and at ECNP on Saturday October 11th in Amsterdam, the Netherlands.

First Published: 3rd October 2025

Image of ISCTM + ECNP logos alongside Cumulus branding

Cumulus Neuroscience will present data at two international conferences in Amsterdam, the Netherlands in October: the International Society for CNS Clinical Trials Methodology (ISCTM) Autumn Conference, and the 38th European Neuropsychopharmacology conference.


"We’re excited to present data at these conferences that also show the validity of multimodal digital biomarkers in neuropsychiatry, whether collected in the clinic or in the home. Additionally, we show how these biomarkers’ superior sensitivity to progression can lead to streamlined study designs."

Brian Murphy, PhD
Chief Scientific Officer and Co-Founder, Cumulus Neuroscience

"The NeuLogiq Platform was purpose-built in collaboration with 10 top biopharma companies to generate objective clinical quality data in CNS Clinical Trials, with an initial focus in Alzheimer’s dementia" said Brian Murphy, PhD, Co-Founder and Chief Scientific Officer of Cumulus. "We’re excited to present data at these conferences that also show the validity of multimodal digital biomarkers in neuropsychiatry, whether collected in the clinic or in the home. Additionally, we show how these biomarkers’ superior sensitivity to progression can lead to streamlined study designs."

The posters were accepted by the ISCTM and ECNP Scientific Program Committees for presentation at the meetings and online. Live poster presentation details are as follows:

International Society for CNS Clinical Trials and Methodology (ISCTM) Autumn Conference
  • Title: Streamlining CNS clinical research with digital endpoints – the trade-off between shorter versus smaller trial designs
  • Date & Time: Friday 10th October 2025, 17:45-19:15 PM CEST
  • Session: Formal poster session
European College of Neuropsychopharmacology (ECNP)
Poster 1
  • Title: Scalable Digital Endpoints Improve Sensitivity to Cognitive Change and Can Drive Efficiencies in CNS Clinical Trials
  • Date & Time: Saturday, October 11, 2025: 12:00 – 13:25
  • Poster Number: PS01-0068
  • Session: Poster Session
Poster 2, in partnership with Delix Therapeutics:
  • Title: Deploying User-Friendly Portable EEG to Measure Response to a Novel Antidepressant with Resting and Task-Driven Neurophysiological Endpoints
  • Date & Time: Saturday, October 11, 2025: 19:00 – 19:30
  • Poster Number: EP02-0103
  • Session: Online

Cumulus supports precision in CNS clinical trials for its industry partners by enabling remote monitoring of patients across multiple domains of brain function. To learn more, visit www.cumulusneuro.com.

About Delix Therapeutics

Delix Therapeutics is a clinical-stage neuroscience company focused on harnessing the power of novel neuroplasticity-promoting therapeutics to better treat patients struggling with difficult-to-treat neuropsychiatric and neurological disorders. The company's compounds are small molecules capable of rapidly inducing structural and functional neural changes in targeted areas of the brain. Through its novel Neuroplastogen Platform, Delix is pioneering a new class of fast-acting outpatient pharmacotherapies and rapidly advancing through preclinical and clinical development to bring patients FDA-approved medicines that are intended to serve several unmet needs and enhance the psychiatric treatment paradigm for patients and providers.

Back to Cumulus News